Safusidenib (AB-218, DS-1001)
J201 Phase 2
Nuvation Bio · Phase 2 · Active, not recruiting · Enrollment 25
| Arm | Reported safety |
|---|---|
| Safusidenib 250 mg BID | n/r |
A count stays a count. This page does not turn a count into a percent.
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
Safusidenib (AB-218, DS-1001)
Nuvation Bio · Phase 2 · Active, not recruiting · Enrollment 25
| Arm | Reported safety |
|---|---|
| Safusidenib 250 mg BID | n/r |
A count stays a count. This page does not turn a count into a percent.